Vistagen Therapeutics, Inc. VTGN 深 滬
等待開盤 06-25 09:30:00 美东时间
0.6648
+0.033
+5.14%
華盛通- 最 高0.6716
- 今 開0.615
- 成交量 54.68万股
- 最 低 0.6103
- 昨 收 0.6323
- 總市值 2727.84万
- 52周最高 5.14
- 市盈率 靜 --
- 換手率 1.33%
- 52周最低 0.43
- 委 比 98.50%
- 總股本 4103.25万
- 歷史最高 495.00
- 量 比 0.28
- 振 幅 9.69%
- 歷史最低 0.43
- 每 手 1
- 風險率 1.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $465.0...
06-16 05:18
VistaGen Completes Phase 3 PALISADE-4 Trial Milestone
VistaGen Therapeutics ( ($VTGN) ) just unveiled an update. On May 8, 2026, Vist...
05-09 06:07
Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder, With Topline Results Expected In Q2
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
05-08 19:42
VistaGen completes last patient visit in PALISADE-4 Phase 3 fasedienol trial
VistaGen completes last patient visit in PALISADE-4 Phase 3 fasedienol trial VistaGen completed last patient last visit in randomized, double-blind, placebo-controlled portion of PALISADE-4 Phase 3 study of fasedienol nasal spray for acute treatment of social anxiety disorder. Topline results have n
05-08 19:30
VistaGen Advances Refisolone Nasal Spray in U.S. Phase 2
VistaGen Therapeutics ( ($VTGN) ) has shared an announcement. On April 22, 2026...
04-29 04:31
Vistagen Receives "Study May Proceed" Letter From FDA Under IND Application For Refisolone Nasal Spray For Treatment Of Vasomotor Symptoms Due To Menopause
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
04-22 20:35
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BNB Plus (NASDAQ:BNBX) stock moved upwards by 12.7% to $0.65 during Tu...
04-15 05:05
VistaGen Showcases Intranasal Pherine Pipeline in New Presentation
The latest update is out from VistaGen Therapeutics ( ($VTGN) ). On March 16, 2...
03-17 04:29
Class action lawsuit targets VistaGen Therapeutics over alleged misleading clinical trial statements
Class action lawsuit targets VistaGen Therapeutics over alleged misleading clinical trial statements A securities class action lawsuit has been filed against VistaGen on behalf of shareholders who purchased securities between April 1, 2024 and December 16, 2025. The complaint alleges the company mad
03-11 21:03
BRIEF-Vistagen Therapeutics Implements 20% Workforce Reduction
BRIEF-Vistagen Therapeutics Implements 20% Workforce Reduction March 11 (Reuters) - VistaGen Therapeutics Inc VTGN.O : VISTAGEN THERAPEUTICS INC - IMPLEMENTS 20% WORKFORCE REDUCTION ON MARCH 5, 2026 - SEC FILING VISTAGEN THERAPEUTICS INC - REDUCTION SUPPORTS CASH MANAGEMENT AND PALISADE PROGRAM CLIN
03-11 19:14
